Related Experiment Video
Updated: Apr 28, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
KPT-330 has antitumour activity against non-small cell lung cancer
1Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background:
We investigated the biologic and pharmacologic activities of a chromosome region maintenance 1 (CRM1) inhibitor against human non-small cell lung cancer (NSCLC) cells both in vitro and in vivo.
Methods:
The in vitro and in vivo effects of a novel CRM1 inhibitor (KPT-330) for a large number of anticancer parameters were evaluated using a large panel of 11 NSCLC cell lines containing different key driver mutations. Mice bearing human NSCLC xenografts were treated with KPT-330, and tumour growth was assessed.
Results:
KPT-330 inhibited proliferation and induced cell cycle arrest and apoptosis-related proteins in 11 NSCLC cells lines. Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. Human NSCLC tumours growing in immunodeficient mice were markedly inhibited by KPT-330. Also, KPT-330 was effective even against NSCLC cells with a transforming mutation of either exon 20 of EGFR, TP53, phosphatase and tensin homologue, RAS or PIK3CA, suggesting the drug might be effective against a variety of lung cancers irrespective of their driver mutation.
Conclusions:
Our results support clinical testing of KPT-330 as a novel therapeutic strategy for NSCLC.
Insights
A novel chromosome region maintenance 1 (CRM1) inhibitor, KPT-330, shows significant anti-cancer activity against non-small cell lung cancer (NSCLC) cells. It effectively inhibits tumor growth in vivo and demonstrates potential across various driver mutations.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide.
- Targeted therapies are crucial for improving outcomes in NSCLC patients.
- Chromosome region maintenance 1 (CRM1) is a potential therapeutic target in cancer.
Purpose of the Study:
- To evaluate the biologic and pharmacologic activities of a novel CRM1 inhibitor, KPT-330.
- To assess the efficacy of KPT-330 against a panel of NSCLC cell lines with diverse driver mutations.
- To determine the in vitro and in vivo effects of KPT-330 on NSCLC growth and survival.
Main Methods:
- In vitro studies using 11 NSCLC cell lines with various key driver mutations.
- In vivo studies involving mice bearing human NSCLC xenografts treated with KPT-330.
- Assessment of anticancer parameters including proliferation, cell cycle arrest, apoptosis, and tumor growth inhibition.
Main Results:
- KPT-330 inhibited proliferation and induced apoptosis in NSCLC cell lines.
- Combination therapy with KPT-330 and cisplatin showed synergistic cell kill.
- KPT-330 markedly inhibited NSCLC tumor growth in vivo, effective across multiple driver mutations (EGFR, TP53, PTEN, RAS, PIK3CA).
Conclusions:
- KPT-330 exhibits potent anti-cancer activity against NSCLC.
- The drug's efficacy across various driver mutations suggests broad applicability.
- Clinical testing of KPT-330 as a novel therapeutic strategy for NSCLC is warranted.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
